Macrocure Ltd., of Petach Tikva, Israel, said results of a phase III trial of Curexcell in the treatment of diabetic foot ulcers (DFUs) did not meet its primary endpoint, failing to show a statistically significant proportion of subjects with complete closure at 16 weeks and sustained complete closure for four additional weeks.